Roche has announced successful Phase III trial outcomes for central nervous system (CNS)-penetrant BTK inhibitor fenebrutinib, meeting primary endpoints in both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) studies. The reversible non-covalent inhibitor demonstrated superior annualised relapse rate (ARR) reduction versus teriflunomide in the FENhance 2 trial, and non-inferiority to ocrelizumab in delaying confirmed disability progression in the FENtrepid study, with numerical benefits observed as early as week 24. Fenebrutinib's dual mechanism inhibits B-cell activation and microglial function, addressing an unmet need in progressive MS affecting 15% of patients, where ocrelizumab remains the only therapy approved in the US market.

The global MS prevalence exceeds 2.9 million patients, with 85% presenting the relapsing-remitting form characterised by inflammatory attacks and disability progression. Fenebrutinib's high selectivity profile shows 130-fold preference for BTK over other kinases, supporting a favourable safety profile in a chronic administration setting. Roche plans regulatory submissions based on robust data from the 736-patient FENhance 2 trial and the 985-participant FENtrepid study, positioning fenebrutinib as a potential first oral therapy for PPMS and a new option for RMS patients failing first-line treatments.

PharmCube's NextBiopharm® database shows that Roche's candidate ranks third globally in terms of development after Innovent/Lilly's pirtobrutinib and Hansoh's rocbrutinib. Click here to request a free trial for NextBiopharm®.